Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents
Chiang A, Madison R, Assaf Z, Fine A, Cao Y, Gjoerup O, Huang Y, Jin D, Hughes J, Antic V, Young A, Fabrizio D, Shames D, Maund S, Exarchos A, Lakhanpal S, Zuniga R, Pasquina L, Schulze K. Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents. JTO Clinical And Research Reports 2025, 100829. DOI: 10.1016/j.jtocrr.2025.100829.Peer-Reviewed Original ResearchSmall cell lung cancerReal-world progression-free survivalCirculating tumor DNAReal-world overall survivalCirculating tumor DNA dynamicsTumor fractionTumor response to immunotherapyLung cancer treated with chemotherapyCancer treated with chemotherapyProgression-free survivalResponse to immunotherapyCell lung cancerNon-small cellTumor imagingChemo-ImmunotherapyTumor responseOverall survivalTherapy initiationTumor DNAExploratory cohortTargeted therapyCtDNA quantificationTargeted agentsTreatment modalitiesTreatment regimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply